查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049586

互聯藥物輸送設備市場規模、佔有率、趨勢和預測：按產品、最終用戶、技術和地區分類，2026-2034年

Connected Drug Delivery Devices Market Size, Share, Trends, and Forecast by Product, End User, Technology, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2025年全球互聯藥物輸送設備市場規模為13.32億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以22.21%的複合年成長率成長，到2034年達到85.204億美元。目前，北美在互聯藥物輸送設備市場佔據主導地位，預計2025年市佔率將超過41.2%。該地區市場佔有率的成長主要得益於醫療技術的進步、連網型設備的高普及率、慢性病盛行率的上升以及有利的法規結構。

新冠疫情加速了遠端醫療藥物傳輸設備市場的應用。疫情導致患者前往醫療機構就診的次數大幅下降，對可用於居家自我監測和藥物管理的設備需求激增。這凸顯了確保病人用藥依從性和在居家照護環境中進行高效治療管理的重要性。疫情進一步推動了數位醫療技術的創新，而遠端醫療報銷政策的擴大也促進了智慧藥物輸送設備的普及。

氣喘、糖尿病和心血管疾病等慢性病的日益普遍，推動了對更有效率、更精準的藥物傳遞方式的需求。連網藥物傳輸設備透過確保合適的劑量和改善整體治療效果，為長期健康管理提供了解決方案。此外，連網型設備透過提供提醒、劑量追蹤和通知等功能，有助於解決日益嚴重的用藥依從性問題。這些功能確保患者按時服藥並遵循處方治療方案，這對治療效果至關重要。同時，感測器技術、無線通訊以及與行動應用程式和醫療平台整合的創新，正在增強連網藥物傳輸設備的功能。這些進步使設備能夠提供更精準的追蹤、監測和即時回饋，在臨床和家庭環境中都展現出卓越的療效。

由於糖尿病、氣喘和心血管疾病等慢性病的日益普遍，美國在互聯藥物輸送設備 (DMD) 的市場佔有率中佔據重要地位，這些疾病需要高效可靠的藥物輸送解決方案。 DMD 透過確保精準給藥和提高用藥依從性，有助於改善疾病管理。此外，美國食品藥物管理局(FDA) 已為互聯醫療設備建立了清晰的法規結構，促進了創新和數位健康解決方案的普及應用。同時，遠端醫療和連網型設備的保險覆蓋範圍不斷擴大，也使患者和醫療專業人員更容易獲得這些技術。 2024 年，BIOCORP 宣布為賽諾菲 SoloStar 胰島素筆開發的 SoloSmart® 智慧感測器已獲得 FDA 510(k)核准。該設備透過追蹤胰島素劑量、注射日期和時間，並將這些資訊傳輸到數位應用程式，有助於改善糖尿病管理。這是 BIOCORP 的 Mallya 平台獲得的第二個 FDA核准。

互聯藥物輸送設備市場趨勢：

人口老化的進程

隨著人口老化，罹患糖尿病、高血壓和心血管疾病等慢性病的風險日益增加。連網藥物輸送設備在有效管理這些疾病方面發揮著至關重要的作用，它們能夠確保藥物的精準給藥和監測。此外，這些設備還具備提醒、劑量追蹤和自動將記錄傳輸給醫療專業人員等功能，簡化治療方案的發展。連網藥物輸送設備能夠遠端追蹤用藥依從性和健康指標，使醫療服務提供者能夠及早發現問題，並為居家養老提供支援。世界衛生組織（WHO）網站上發表的報導預測，到2050年，全球整體60歲以上人口數量將加倍，達到近21億。預計這將對產品需求產生積極影響，並顯著推動連網藥物輸送設備市場的成長。

慢性阻塞性肺病（COPD）盛行率增加

根據世界衛生組織（世衛組織）網站2023年更新的信息，70歲以下人群中約90%的慢性阻塞性肺病（COPD）相關死亡病例發生在低收入和中等收入國家。 COPD患者需要精準控制藥物治療，包括支氣管擴張劑和皮質類固醇。連網藥物輸送裝置可確保正確的劑量和給藥時間，這對於有效控制COPD症狀至關重要。此外，連網型設備還能監測吸入技巧，並向患者提供即時回饋。這有助於COPD患者最佳化吸入技巧，最大限度地提高藥物療效。因此，COPD是一種慢性疾病，需要持續監測症狀和肺功能。連網型設備能夠遠端監測COPD患者的健康狀況，包括肺功能測試和症狀監測，有助於及早發現病情惡化並及時調整治療方案。

快速成長的遠端醫療市場

根據IMARC Group的報告，2023年全球遠端醫療市場規模達747億美元。遠端醫療平台支援醫護人員與病患之間的遠距會診，為尋求醫療服務的病患提供更方便的途徑。連網藥物輸送設備能夠即時追蹤患者的用藥依從性、治療反應和整體健康狀況，進而與遠距遠端醫療相輔相成。這些設備提供有關藥物狀態、給藥時間和患者病情的重要數據，尤其有利於糖尿病、高血壓和呼吸系統疾病等慢性病的管理。此外，將遠端醫療平台整合，使醫護人員能夠遠端調整劑量、最佳化治療方案並持續監測患者的病情進展。這種協同作用不僅確保了更精準、更個人化的醫療服務，還透過提供來自患者實際環境的可操作訊息，提高了遠距遠端醫療會診的有效性。此類整合透過支援預防性管理和改善患者預後，減少了患者頻繁到院就診的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球互聯藥物輸送設備市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 聯網感測器
    • 主要部分
      • 用於連接式吸入器的感測器
      • 可連接的噴射感測器
  • 整合連網型設備
    • 主要部分
      • 連接式吸入裝置
      • 連接式注射裝置

第7章 市場區隔：依最終用戶分類

  • 醫院和醫療保健機構
  • 居家照護

第8章 市場區隔：依技術分類

  • Bluetooth
  • NFC
  • 其他技術

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Adherium Limited
    • BioCorp Production
    • Cohero Health Inc.（AptarGroup Inc.）
    • Elcam Medical ACS. Ltd
    • Findair Sp. z oo
    • Merck KGaA
    • Phillips Medisize（Molex LLC）
    • Propeller Health（Resmed Inc.）
    • Teva Pharmaceutical Industries Ltd.
    • West Pharmaceutical Services Inc.
Product Code: SR112026A3738

The global connected drug delivery devices market size was valued at USD 1,332.0 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 8,520.4 Million by 2034, exhibiting a CAGR of 22.21% from 2026-2034. North America currently dominates the connected drug delivery devices market share, holding a market share of over 41.2% in 2025. The region's connected drug delivery devices market share is driven by advancements in healthcare technology, high adoption of connected devices, increasing chronic disease prevalence, and supportive regulatory frameworks.

The COVID-19 pandemic accelerated the adoption of remote healthcare solutions within the connected drug delivery devices market outlook. Due to this, the number of patient visitations in healthcare facilities was also very low. There was intense demand for devices that could be used for self-monitoring and self-management of medications at home. This placed emphasis on ensuring medication adherence and efficient treatment management in the home care setting. The pandemic boosted innovation in digital health technologies further, and growth in reimbursement policies for telehealth supported the expansion of connected drug delivery devices.

The prevalence of chronic conditions, which include asthma, diabetes, and cardiovascular diseases is driving the demand for more efficient and accurate medication delivery methods. Connected drug delivery devices offer a solution by ensuring proper dosing and improving overall treatment outcomes, making them essential for managing long-term health conditions. in addition, connected devices help address the growing challenge of medication non-adherence by offering features like reminders, dosage tracking, and notifications. They ensure that patients take their medications on time and follow prescribed regimens, which is crucial for the effectiveness of treatments. Moreover, innovation in sensor technology, wireless communication, and integration with mobile applications and healthcare platforms is enhancing the functionality of connected drug delivery devices. These advancements allow devices to provide more accurate tracking, monitoring, and real-time feedback, making them highly effective in both clinical and home settings.

The United States plays a crucial role in the connected drug delivery devices market share, driven by the rising prevalence of chronic diseases like diabetes, asthma, and cardiovascular conditions, which require efficient and reliable medication delivery solutions. Connected drug delivery devices help improve disease management by ensuring accurate dosing and enhancing medication adherence. Furthermore, the U.S. Food and Drug Administration (FDA) is establishing clear regulatory frameworks for connected medical devices, encouraging innovation and the adoption of digital health solutions. Additionally, expanding reimbursement policies for telehealth and connected devices are helping make these technologies more accessible to patients and healthcare providers. In 2024, BIOCORP revealed it obtained FDA 510(k) approval for SoloSmart(R), an intelligent sensor created for Sanofi's SoloStar insulin pens. The device tracks insulin units, injection date, and time, sending information to a digital app, improving diabetes management. This represents the second approval from the FDA for BIOCORP's Mallya platform.

CONNECTED DRUG DELIVERY DEVICES MARKET TRENDS:

GROWING AGING POPULATION

As people are aging, they are encountering greater risk of continual ailments like diabetes, high blood pressure, and cardiovascular diseases. Connected drug delivery devices play an important role in handling those situations effectively by ensuring precise medicinal drug dosing and monitoring. Moreover, these devices can simplify those regimens through reminders, tracking dosages, and transmitting records mechanically to healthcare companies. Connected drug delivery devices allow remote tracking of medicine adherence and fitness parameters. This allows healthcare companies to intervene the issues early, thus supporting aging in place. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 Billion worldwide. This is projected to positively impact the product demand while significantly boosting the connected drug delivery devices market growth.

RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

As per the content updated in 2023 on the website of the World Health Organization (WHO), nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries. COPD patients require precise and managed delivery of medicinal drugs which include bronchodilators and corticosteroids. Connected drug delivery devices ensure correct dosing and timely administration, which is vital for coping with COPD signs effectively. In addition, connected devices can monitor inhalation strategies and provide feedback to patients in actual time. This allows COPD sufferers optimize their inhalation approach, making sure that they obtain the maximum benefits from their medicines. In line with this, COPD is a revolutionary disease that requires continuous monitoring of symptoms and lung function. Connected devices permit for remote monitoring of COPD patients' fitness fame, consisting of lung feature tests and symptom monitoring, facilitating early detection of exacerbations and timely adjustments to treatment plans.

THRIVING TELEMEDICINE SECTOR

The IMARC Group's report shows that the global telemedicine market reached USD 74.7 Billion in 2023. Telemedicine platforms facilitate remote consultations between healthcare providers and patients, offering greater accessibility and convenience for individuals seeking healthcare. Connected drug delivery devices supplement telemedicine by enabling real-time tracking of patients' medication adherence, treatment response, and overall health status. These devices provide vital data on drug intake, dosage timing, and patient condition, which is especially beneficial for managing chronic conditions such as diabetes, hypertension, and respiratory illnesses. Additionally, the integration of connected drug delivery devices with telehealth platforms allows healthcare providers to remotely adjust medication dosages, fine-tune treatment plans, and monitor patient progress continuously. This synergy not only ensures more accurate and personalized care but also enhances the effectiveness of telemedicine consultations by offering actionable insights directly from the patient's environment. Such integration supports proactive management and improves patient outcomes, reducing the need for frequent in-person visits.

CONNECTED DRUG DELIVERY DEVICES INDUSTRY SEGMENTATION:

ANALYSIS BY PRODUCT:

  • Connected Sensors
    • Connected Inhaler Sensors
    • Connectable Injection Sensors
  • Integrated Connected Devices
    • Connected Inhalation Devices
    • Connected Injection Devices

Integrated connected devices hold the biggest market share, accounting 56.8% in 2025. Integrated connected devices (connected inhalation devices and connected injection devices) represent the largest segment attributed to their ability to combine medication delivery with advanced monitoring features, significantly enhancing patient care. These devices provide real-time tracking of medication usage, helping patients adhere to prescribed regimens and improving overall treatment outcomes. For instance, connected inhalers monitor usage frequency, technique, and dosage, while connected injection devices track injection sites, doses, and timing, offering valuable data for both patients and healthcare providers. The integration of sensors and connectivity allows for immediate feedback, helping to identify and address issues like missed doses, improper techniques, or potential side effects. Furthermore, these devices enable remote monitoring by healthcare professionals, facilitating personalized treatment adjustments. As a result, integrated connected devices offer a comprehensive solution that enhances convenience, precision, and patient engagement, driving their dominance in the market.

ANALYSIS BY END USER:

  • Hospitals and Healthcare Providers
  • Homecare

Hospitals and healthcare providers stand as the largest component in 2025, holding 59.3% of the market share. Hospitals and healthcare providers lead the market because of their critical need for efficient patient care, improved medication adherence, and better treatment outcomes. These institutions rely on connected devices to streamline medication management, monitor patient progress, and enable more personalized treatments. With the growing prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, healthcare providers are adopting connected drug delivery systems to ensure accurate dosing and track medication usage in real time. The integration of connected devices into healthcare settings also supports remote monitoring, reducing the need for frequent hospital visits, and providing a more convenient and cost-effective solution for both patients and providers. Moreover, hospitals benefit from the real-time data provided by connected devices, which enhances decision-making and patient safety. As healthcare systems move toward more digital and data-driven approaches, hospitals and healthcare providers continue to drive demand for connected drug delivery technologies.

ANALYSIS BY TECHNOLOGY:

  • Bluetooth
  • NFC
  • Other Technologies

In 2025, Bluetooth represented the largest segment, accounting 61.8% of the market share. Bluetooth leads the market due to its numerous advantages in healthcare applications. Its low power usage is a critical factor, allowing devices such as insulin pens, inhalers, and wearable injectors to operate efficiently for long periods without frequent battery replacements, enhancing patient compliance and reducing operational costs. Bluetooth's wireless communication capabilities enable seamless data transmission between drug delivery devices and mobile applications or healthcare platforms, providing real-time insights into medication usage, dosage, and adherence. This capability is vital for remote monitoring, allowing healthcare providers to track patient progress and adjust treatment plans as needed. Additionally, Bluetooth is widely compatible with a range of devices, including smartphones, tablets, and other medical equipment, ensuring ease of integration into existing healthcare systems. The technology's reliability, security, and cost-effectiveness make Bluetooth a natural fit for the connected drug delivery device market, driving its widespread adoption globally.

REGIONAL ANALYSIS:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share at 41.2%. North America dominates the market owing to the increasing healthcare expenditure. According to the information revised in 2023 on the Centers for Medicare & Medicaid Services website, U.S. health care expenditures increased by 4.1 percent in 2022, totaling USD 4.5 trillion or USD 13,493 for each individual. The rising healthcare spending indicates a stronger focus on enhancing patient results and lowering total healthcare expenses via innovative technologies. Besides this, the region has a strong presence of pharmaceutical companies and medical device manufacturers that are investing heavily in research and development (R&D) activities of connected drug delivery devices. These companies are leveraging advancements in IoT and digital connectivity to develop innovative devices that enhance medication adherence, patient monitoring, and overall treatment outcomes. Additionally, beneficial reimbursement policies and encouraging regulatory frameworks in the area aid in the swift expansion of this market segment.

KEY REGIONAL TAKEAWAYS:

UNITED STATES CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS

In North America, the market share for the United States was 81.80% of the total. The adoption of connected drug delivery devices has surged, driven by increasing investments aimed at enhancing the healthcare infrastructure. For instance, U.S. healthcare companies securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. These devices enable real-time monitoring and improved medication adherence, appealing to both providers and patients. With more resources allocated to integrating advanced technologies, healthcare systems are better equipped to offer personalized treatment solutions. Such investments pave the way for the incorporation of connected solutions into clinical workflows, simplifying chronic disease management and reducing hospital readmissions. Patients benefit from timely alerts and dosage tracking, while healthcare providers gain access to valuable data that improves decision-making. Advanced connectivity features, combined with the demand for efficient patient care, are driving this shift. The growing focus on reducing long-term treatment costs and improving outcomes favoring the connected drug delivery devices market forecast.

EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS

An aging population has significantly influenced the adoption of connected drug delivery devices, as these systems address the unique healthcare challenges of older adults. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. With age-related conditions requiring consistent and precise medication, such devices help ensure adherence to prescribed regimens. They simplify the administration process for individuals with limited mobility or cognitive decline by providing automated reminders and easy-to-use interfaces. Additionally, caregivers can remotely monitor medication schedules and adjust treatments as needed, enhancing the quality of care. This focus on supporting aging individuals fosters increased interest in technologies that improve independence and safety. Furthermore, healthcare providers benefit from access to detailed medication data, enabling them to identify trends and tailor therapies effectively. As the population continues to age, the demand for solutions that enhance patient care and reduce hospitalizations is driving the widespread adoption of these devices in managing chronic conditions.

ASIA PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS

The rise of digitalization and telemedicine has fuelled the connected drug delivery devices market demand. For instance, Indian digital healthcare segment is estimated to grow 10x from USD 2.7 Billion in 2022 to USD 37 Billion by 2030. These devices seamlessly integrate with digital platforms, facilitating remote patient monitoring and enhanced medication adherence. As healthcare providers are continuously relying on telehealth solutions, the requirement for connected systems that bridge the gap between patients and caregivers has become more pronounced. Digital ecosystems now include features that allow users to share medication data with professionals in real-time, streamlining treatment processes. Patients benefit from reminders and data tracking, while caregivers can monitor compliance remotely. This digital evolution has transformed the way chronic diseases are managed, emphasizing convenience and accessibility. With the growing emphasis on telemedicine, connected devices are becoming indispensable tools in ensuring continuity of care and improving therapeutic outcomes, particularly in areas that rely heavily on virtual healthcare models.

LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS

Chronic obstructive pulmonary disease is a significant factor driving the use of connected drug delivery devices. For instance, among the 22,663,091 deaths that occurred from 2000 to 2019 in Brazil, 1,132,968 had COPD mentioned as a cause of death. These devices provide patients with real-time feedback and reminders, ensuring consistent use of prescribed treatments. By monitoring inhaler usage and patterns, the devices help optimize medication adherence, leading to improved outcomes. For healthcare providers, the ability to track usage remotely offers insights into disease progression and effectiveness of treatments. This connectivity facilitates timely interventions, reducing exacerbations and hospital visits. The increased awareness of managing respiratory conditions with precision and ease makes these devices a preferred choice for long-term care, aligning with the growing focus on effective management of chronic diseases.

MIDDLE EAST AND AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET ANALYSIS

The expansion of healthcare facilities has bolstered the adoption of connected drug delivery devices, addressing the need for advanced patient-centric solutions. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. These devices integrate seamlessly into hospital and clinic settings, providing real-time data to enhance treatment accuracy. Their ability to simplify medication management while reducing errors aligns with the objectives of modern healthcare environments. Patients benefit from enhanced compliance tools, while professionals utilize the collected data for informed decision-making. As healthcare systems evolve, incorporating connected devices ensures streamlined operations and improved patient experiences. This growth reflects the increasing emphasis on leveraging technology to optimize care delivery in expanding medical infrastructures.

COMPETITIVE LANDSCAPE:

Major participants in the market are concentrating on technological advancement and strategic collaborations to enhance their product range. Organizations are putting substantial resources into creating sophisticated features, including real-time tracking, data analysis, and compatibility with mobile apps, to boost patient involvement and enhance treatment results. They are prioritizing obtaining regulatory approvals to ensure their devices comply with industry standards and achieve wider market acceptance. Moreover, numerous stakeholders are partnering with healthcare providers, technology firms, and regulatory agencies to facilitate the integration of connected devices in diverse healthcare environments. In 2024, Medtronic revealed that its Simplera(TM) continuous glucose monitor (CGM) received FDA approval, offering a compact, integrated device. Medtronic announced a worldwide collaboration with Abbott to combine Abbott's CGM technology with Medtronic's intelligent insulin delivery systems. This partnership seeks to improve access to sophisticated diabetes management resources.

The report provides a comprehensive analysis of the competitive landscape in the connected drug delivery devices market with detailed profiles of all major companies, including:

  • Adherium Ltd.
  • BioCorp Production
  • Cohero Health Inc. (AptarGroup Inc.)
  • Elcam Medical ACS. Ltd
  • Findair Sp. z o. o.
  • Merck KGaA
  • Phillips Medisize (Molex LLC)
  • Propeller Health (Resmed Inc.)
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services Inc.

Key Questions Answered in This Report

  • 1.How big is the connected drug delivery devices market?
  • 2.What is the expected growth rate of the global connected drug delivery devices market during 2026-2034?
  • 3.What are the factors driving the connected drug delivery devices market?
  • 4.What are the key regions in the global connected drug delivery devices market?
  • 5.Who are the key players/companies in the global connected drug delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Connected Drug Delivery Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Connected Sensors
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Connected Inhaler Sensors
      • 6.1.2.2 Connectable Injection Sensors
    • 6.1.3 Market Forecast
  • 6.2 Integrated Connected Devices
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Connected Inhalation Devices
      • 6.2.2.2 Connected Injection Devices
    • 6.2.3 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals and Healthcare Providers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Homecare
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Bluetooth
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 NFC
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Other Technologies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adherium Limited
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 BioCorp Production
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Cohero Health Inc. (AptarGroup Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Elcam Medical ACS. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Findair Sp. z o. o.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck KGaA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Phillips Medisize (Molex LLC)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Propeller Health (Resmed Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Teva Pharmaceutical Industries Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 West Pharmaceutical Services Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Connected Drug Delivery Devices Market: Major Drivers and Challenges
  • Figure 2: Global: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Connected Drug Delivery Devices Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Connected Drug Delivery Devices Market: Breakup by End User (in %), 2025
  • Figure 6: Global: Connected Drug Delivery Devices Market: Breakup by Technology (in %), 2025
  • Figure 7: Global: Connected Drug Delivery Devices Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Connected Drug Delivery Devices (Connected Sensors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Connected Drug Delivery Devices (Connected Sensors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Connected Drug Delivery Devices (Integrated Connected Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Connected Drug Delivery Devices (Integrated Connected Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Connected Drug Delivery Devices (Hospitals and Healthcare Providers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Connected Drug Delivery Devices (Hospitals and Healthcare Providers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Connected Drug Delivery Devices (Homecare) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Connected Drug Delivery Devices (Homecare) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Connected Drug Delivery Devices (Bluetooth) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Connected Drug Delivery Devices (Bluetooth) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Connected Drug Delivery Devices (NFC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Connected Drug Delivery Devices (NFC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Connected Drug Delivery Devices (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Connected Drug Delivery Devices (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: North America: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: North America: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: United States: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: United States: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Canada: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Canada: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Asia-Pacific: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Asia-Pacific: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: China: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: China: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Japan: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Japan: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: India: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: India: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: South Korea: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: South Korea: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Australia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Australia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Indonesia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Indonesia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Europe: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Europe: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Germany: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Germany: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: France: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: France: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: United Kingdom: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: United Kingdom: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Italy: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Italy: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Spain: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Spain: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Russia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Russia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Latin America: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Latin America: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Brazil: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Brazil: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Mexico: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Mexico: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Middle East and Africa: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Middle East and Africa: Connected Drug Delivery Devices Market: Breakup by Country (in %), 2025
  • Figure 70: Middle East and Africa: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Global: Connected Drug Delivery Devices Industry: SWOT Analysis
  • Figure 72: Global: Connected Drug Delivery Devices Industry: Value Chain Analysis
  • Figure 73: Global: Connected Drug Delivery Devices Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Connected Drug Delivery Devices Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Connected Drug Delivery Devices Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 4: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Connected Drug Delivery Devices Market: Competitive Structure
  • Table 7: Global: Connected Drug Delivery Devices Market: Key Players